Clozapine-balancing the body and the mind.
暂无分享,去创建一个
[1] J. MacCabe,et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis , 2021, The British Journal of Psychiatry.
[2] A. Tanskanen,et al. 20‐year follow‐up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20) , 2020, World psychiatry : official journal of the World Psychiatric Association.
[3] D. Cohen,et al. Systematic review and meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy , 2020, The Australian and New Zealand journal of psychiatry.
[4] C. Correll,et al. Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1–12.5 Years , 2019, Schizophrenia bulletin.
[5] M. Large,et al. Meta‐analysis examining the epidemiology of clozapine‐associated neutropenia , 2018, Acta psychiatrica Scandinavica.
[6] D. Siskind,et al. The impact of clozapine on hospital use: a systematic review and meta‐analysis , 2017, Acta psychiatrica Scandinavica.
[7] H. Möller,et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. , 2017, The American journal of psychiatry.
[8] D. Siskind,et al. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis , 2016, British Journal of Psychiatry.
[9] Alexandra G. Smith,et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network , 2011, British Journal of Cancer.